FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1555-1556 October 11, 2007 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Rennert, G. PubMed Citation

To the Editor: Rennert et al. (July 12 issue)¹ report that a BRCA1 or BRCA2 mutation was not a significant predictor of mortality from breast cancer in an Israeli population-based cohort. However, 43% of potential cases were not included because tumor samples or medical records could not be retrieved, and excluded cases were more likely than included cases to be fatal. If BRCA1 carriers have more aggressive tumors,² leading to earlier death, this could result in a spuriously improved prognosis (Neyman bias). In addition, the investigators did not study tumor grade (associated with mutation status),³ nor did they identify prognostic . . . [Full Text of this Article]

This article has been cited by other articles:

• Roukos, D. H., Lykoudis, E., Liakakos, T. (2008). Genomics and Challenges Toward Personalized Breast Cancer Local Control. JCO 26: 4360-4361 [Full Text]  
• Briasoulis, E., Roukos, D. H. (2008). Contralateral Prophylactic Mastectomy: Mind the Genetics. JCO 26: 1909-1910 [Full Text]